
Markets: Turkish Health Authorities, ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
Batch Size: Small, Medium
Compliance: PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP), FDA (cGMP)
Category / Product: SERVICES, CHEMICAL-SYNTHETIC
Region: Europe
Use: Human, Veterinary
Services: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CARBOGEN AMCIS
Sviluppo e produzione cGMP su media scala inclusa la cromatografia.
Batch Size: Small, Medium
Compliance: PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO
Category / Product: SERVICES, PARTICLE ENGINEERING, BIOLOGICS, CHEMICAL-SYNTHETIC
Region: Europe
Markets: ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
Use: Human, Veterinary
Services: Analytical / QC services, Manufacturing services, Development services, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day)

CARBOGEN AMCIS
Sviluppo e produzione cGMP di API altamente potenti, inclusi coniugati di farmaci anticorpali (ADC).
Markets: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)
Batch Size: Small, Medium
Therapeutic Areas of Expertise (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs
Compliance: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO
Category / Product: SERVICES, PARTICLE ENGINEERING, BIOLOGICS, CHEMICAL-SYNTHETIC
Region: Europe
Use: Human, Veterinary
Services: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CARBOGEN AMCIS
Sviluppo di API altamente potenti e produzione cGMP su piccola scala, tra cui cromatografia e liofilizzazione.
Batch Size: Small
Compliance: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO
Region: Europe
Markets: ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
Use: Human, Veterinary
Services: Analytical / QC services, Manufacturing services, Development services, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)
Category / Product: CHEMICAL-SYNTHETIC

Adragos Pharma
Siamo specializzati nella produzione asettica di prodotti farmaceutici (bio)farmaceutici sterili liofilizzati o liquidi attraverso il riempimento e la finitura.
Batch Size: Small, Medium
Category / Product: FDF / DRUG PRODUCTS
Compliance: EMA (EU GMP), FDA (cGMP)
Region: Europe
Use: Human
Services: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
Markets: PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), NMPA (China), Health Canada (Canada), MHRA (UK)
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)
Controlled Substances: High potential for abuse & no medical use

Senn Chemicals
Sito svizzero di ricerca e sviluppo su peptidi e intermedi peptidici con SPPS, LPPS, sintesi ibrida, scale up in laboratorio, purificazione e analisi.
Batch Size: Small
Category / Product: COSMETICS, SERVICES, PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC
Region: Europe
Services: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

Senn Chemicals
Laboratorio di sintesi organica e di peptidi GMP su piccola scala per progetti clinici, di nicchia e di alto valore che richiedono una produzione flessibile di
Batch Size: Small
Region: Europe
Services: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
Category / Product: PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

Senn Chemicals
Sito svizzero di produzione cGMP per la produzione di LPPS, SPPS e peptidi ibridi dal progetto pilota alla prima scala commerciale.
Batch Size: Medium, Large
Region: Europe
Services: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
Category / Product: PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

Aenova
Centro di competenza solidi convenzionali complessi.
Markets: Turkish Health Authorities, ANVISA (Brazil), FDA (USA), Russian Health Authorities, MFDS (South Korea)
Batch Size: Small, Medium, Large
Category / Product: FDF / DRUG PRODUCTS, NUTRACEUTICALS
Compliance: Roszdravnadzor (Russia GMP), ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO, MFDS/KFDA (Republic of Korea GMP)
Region: Europe
Use: Human
Services: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Aenova
Centro di competenza Capsule di gelatina morbida.
Markets: Turkish Health Authorities, FDA (USA), Russian Health Authorities, EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia)
Batch Size: Small, Medium, Large
Category / Product: FDF / DRUG PRODUCTS, COSMETICS, NUTRACEUTICALS
Compliance: Roszdravnadzor (Russia GMP), EMA (EU GMP), World Health Organization (GMP / HACCP), TGA (Australia GMP), FDA (cGMP), SFDA (Saudi Food & Drug Authority), ISO, TITCK (Turkish Health Authorities), MFDS/KFDA (Republic of Korea GMP)
Region: Europe
Use: Human, Veterinary
Services: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
Therapeutic Areas of Expertise (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (V06) Nutrients
OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)
MAI network supplier
—
Location available after registration
MAI network supplier
Oftalmico e ottico - Soluzioni, sospensioni, emulsioni, unguenti e gel - Struttura approvata dalla FDA.
Location available after registration
Siete un´azienda farmaceutica alla ricerca di un partner CMO o CDMO affidabile per accelerare il processo di sviluppo dei vostri farmaci? Non cercate oltre MAI CDMO Network. La nostra piattaforma di ricerca avanzata vi mette in contatto con una vasta rete di produttori a contratto e organizzazioni di sviluppo qualificate in tutto il mondo.
Perché scegliere MAI CDMO Network?
Come funziona MAI CDMO Network
Vantaggi principali della collaborazione con un CMO/CDMO
Servizi in primo piano
Pronti a trovare il vostro partner CMO/CDMO ideale? Registratevi ora
Esplorate oggi stesso la nostra piattaforma e scoprite come MAI CDMO Network può aiutarvi a raggiungere i vostri obiettivi di sviluppo dei farmaci.